CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

Triggered by ongoing and very successful multi-year collaboration June 1, 2014 CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division of Sanofi , to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen. In 2011, CureVac and Sanofi Pasteur signed a collaboration and license option agreement …